Low-dose prednisone is an effective rescue for deteriorating semen parameters following vasovasostomy

• Published in: International Brazilian Journal of Urology 2024-01, Vol.50 (1), p.58-64
• Main Authors: White, Joshua, Campbell, Katherine, Deebel, Nicholas, Muthigi, Akhil, Mesquita, Francesco Costantini, Campos, Lucas, Egemba, Christabel, Albaraez, Maria Camila Suarez, Ledesma, Braian, Ory, Jesse, Ramasamy, Ranjith
• Format: Article
• Language: English
• Subjects: Original; Prednisone; Semen; Vasovasostomy
• ISSN: 1677-5538; 1677-6119
• DOI: 10.1590/s1677-5538.ibju.2023.0402

ABSTRACT Objective: This retrospective study aimed to evaluate the effectiveness of low-dose prednisone as a rescue therapy for patients with deteriorating semen parameters following vasovasostomy. Materials and Methods: Electronic medical records were queried at the University of Miami with documented CPT code 55400 (Bilateral Vasovasostomy) between January 2016 and April 2023. Records were then reviewed to identify patients who demonstrated ≥50% decrease in semen parameters, specifically sperm concentration, motility and total motile sperm count. Patients who were treated with 6 weeks of low-dose prednisone were identified, and baseline semen parameters and subsequent changes after prednisone therapy were assessed. A Mann-Whitney U Test was used to compare semen parameter changes before and after prednisone. Adverse effects associated with prednisone were monitored. Results: A total of 8 patients were identified with deteriorating semen parameters who were treated with 6 weeks of low-dose prednisone. Following prednisone therapy, all patients demonstrated improvements in total motile sperm count (TMSC), with a median improvement of 6 million. The median relative improvement in TMSC was 433%. Sperm concentration and motility also improved compared to post-operative baseline. No adverse effects were reported during the treatment period. Conclusions: Low-dose prednisone therapy appears to be a safe and effective intervention for managing deteriorating semen parameters following VV. The observed improvements in TMSC suggest the potential of prednisone to rescue patients with delayed failure after VV. Further research with larger sample sizes is warranted to confirm the safety and efficacy of low-dose prednisone as a rescue therapy in this specific patient population. Optimizing VV outcomes is crucial in male infertility, and further exploration of steroid therapy and innovative biotechnologies is warranted.